Alimta

... · IN-FORUM · Subscribe Today Monday, April 18, 2005 Media Partners: Log In PressPass Past 30 Days Archive Classified Jobs Homes Apartments Cars Personals Home News Associated Press Weather Sports Opinion Valley R & R Columnists Business Farm Weddings Obituaries Photography Births Calendar Dining Special Projects Outdoors Corrections Classifieds Internet Access Marketplace Newspaperprints Travel Member Center Archive Company Site Ethics Code E-Mail Index InfoGuide Newspapers in Education Public Notices Resources Subscribe Yellow Pages Eli Lilly 1Q Profit Up Despite Weak Sales By KEN KUSMER AP Business Writer The Associated Press - Monday, April 18, 2005 · advertisement · INDIANAPOLIS, Ind.

Eli Lilly & Co.

on Monday said its profits climbed during the first quarter despite eroding sales of its anti-psychosis drug Zyprexa and attention deficit disorders treatment Strattera, which has a new warning about side effects.

Lilly also said second quarter earnings would fall short of current Wall Street estimates, but it expected to meet investors' expectations for the full year.

Lilly earned $736.6 million, or 68 cents per share, in the January-March period, up from $400.4 million, or 37 cents per share, during the same period a year ago.

The 2004 figures reflected one-time research and development costs of $362.3 million.

Excluding that expense, and assuming the expensing of stoc...

... S&P Upgrades Adobe to Buy .pp16 { display:block; width:180px; height:150px; } New Search Advanced Search Customer Service Register Subscribe to BW Today's News News Archive News Search Special Reports Lifestyle Newsmaker Videos Markets Stocks Funds Sectors Economy & Bonds Investing Glossary Newsletter Sign-Up BUSINESS DIRECTORY Find local experts in: PREMIUM CONTENT MBA Insider ONLINE FEATURES Past Covers Columnists Book Reviews Newsletters BLOGS Brand New Day Deal Flow Tech Beat Well Spent TECHNOLOGY Wildstrom: Tech Maven Product Reviews Startups Special Reports Tech Stats SMALLBIZ Smart Answers Success Stories Trailblazing Companies INVESTING Annual Reports BW 50 S&P Picks & Pans Stock Screeners Free S&P Stock Report SCOREBOARDS Mutual Funds Info Tech 100 S&P 500 B-SCHOOLS MBA Profiles MBA Rankings Who's Hiring Grads BW EXTRAS BW Digital Handheld Edition RSS Feeds Reprints/Permissions Conferences Investor Workshops APRIL 18, 2005 Find More Stories Like This TODAY'S HEADLINES Praying for Good Earnings The Boss on the Sidelines Tip For the Board: "Don't Assume" "Sarbanes-Oxley Is Not Bad" Denny Hastert's Late Payment Tech's Gathering Gloom The Old IT Is Dead.

Long Live the New No Qu...

... SignOnSanDiego.com Business - Lilly earnings rise in first quarter, but outlook is below estimates Weather Fitness Military Obituaries Opinion Politics Science Technology Multimedia Forums Columnists Weblogs Special Reports Solutions Weather U-T Daily Paper U-T E-mail Edition AP Headlines Archives E-mail Newsletters Wireless Edition Noticias en Español Internet Access Lilly earnings rise in first quarter, but outlook is below estimates ASSOCIATED PRESS 5:11 a.m.

April 18, 2005 INDIANAPOLIS, Ind.

– The drugmaker Eli Lilly & Co.

on Monday said its profit climbed in the first quarter, beating expectations on strong sales of newer products, but said its profit for the second quarter would be below current Wall Street estimates.

Earnings rose to $736.6 million, or 68 cents per share, in the January-March period from $400.4 million, or 37 cents per share, a year ago.

Year-ago figures reflect acquired in-process research and development expenses of $362.3 million.

Excluding that expense, and assuming the expensing of stock options, net income for the 2004 quarter was $671.4 million, or 62 cents per share.

The result for the ...